Unifying Heterogeneous Electronic Health Records Systems via Text-Based Code Embedding

Kyunghoon Hur* Jiyoung Lee* Jungwoo Oh KAIST, Republic of Korea PACESUN@KAIST.AC.KR
JIYOUNGLEE0523@KAIST.AC.KR

ojw0123@kaist.ac.kr

Wesley Price

WJPRICE@MIT.EDU

MIT, USA

Younghak Kim MDYHKIM@AMC.SEOUL.KR

Asan Medical Center, University of Ulsan College of Medicine, South Korea

Edward Choi EDWARDCHOI@KAIST.AC.KR

 $KAIST,\ Republic\ of\ Korea$

Abstract

Increase in the use of Electronic Health Records (EHRs) has facilitated advances in predictive healthcare. However, EHR systems lack a unified code system for representing medical concepts. Heterogeneous formats of EHR present a barrier for the training and deployment of state-of-the-art deep learning models at scale. To overcome this problem, we introduce Description-based Embedding, DescEmb, a code-agnostic description-based representation learning framework for predictive modeling on EHR. DescEmb takes advantage of the flexibility of neural language models while maintaining a neutral approach that can be combined with prior frameworks for task-specific representation learning or predictive modeling. We test our model's capacity on various experiments including prediction tasks, transfer learning and pooled learning. DescEmb shows higher performance in overall experiments compared to the code-based approach, opening the door to a text-based approach in predictive healthcare research that is not constrained by EHR structure nor special domain knowledge.

Data and Code Availability This paper uses MIMIC-III and eICU, which are publicly available on the PhysioNet repository (Johnson et al., 2016; Pollard et al., 2018). More details about datasets can be found at Section 3.1. Our code implementation is available is available on Github.¹

1. Introduction

Increased adoption of electronic health record (EHR) systems offers great potential for EHR-based predictive models to improve healthcare quality. Deep learning models have shown comparable or better performance in diagnosing or predicting various medical events. (Lipton et al., 2015; Gulshan et al., 2016; Rank et al., 2020).

However, the heterogeneity of EHR systems among hospitals presents barriers for applications of EHRbased deep learning models. Contemporary EHRs rely on data systems ranging from standardized codes (e.g. ICD9, LOINC) to free-text entry. Therefore, modern deep learning approaches are based on learning the representations of these codes, an approach we refer to as 'code-based embedding'. However, this paradigm does not allow a model to be transferred from one environment to another nor to be trained on large EHR data collected from multiple hospitals that use heterogeneous EHR formats. Consequently, modern deep learning prediction models are missing out on the opportunity to be scaled up. This challenge could be alleviated by mapping codes from one system to another, or by converting all EHR data to Common Data Model (e.g. OMOP, FHIR) (Rajkomar et al., 2018). However, this requires significant human effort and domain knowledge and may not even be possible, depending on the code system at hand.

In this paper, we suggest code-agnostic text-based representation learning. Since each medical code has

^{*} These authors contributed equally

^{1.} https://github.com/hoon9405/DescEmb




Figure 1: CodeEmb and DescEmb concept visualization. (A) CodeEmb: predictive models are trained with code-base embedding. The code encoders and the prediction layers cannot be shared among different hospitals due to heterogeneity of the code systems. (B) DescEmb: predictive models are trained on description-based embeddings derived from the text encoder. Due to the code-agnostic nature of the text-encoder, both the text encoders and the prediction layers can be transferred between different hospitals, unlike (A). (C) Learning from pooled data via DescEmb: we can pool heterogeneous hospital data into one dataset and train jointly, thus increasing the deployment efficiency.

a text description that represents its semantic property, we propose Description-based Embedding, DescEmb. DescEmb adopts a neural text encoder to convert medical codes to contextualized embeddings, allowing us to map medical codes of different formats to the same text embedding space. Figure 1 gives a visual summary of our model framework; instead of directly embedding the medical codes as in (A), the prediction layer takes a series of vectors representing code descriptions passed through a neural text encoder as in (B) and (C). Our principled approach yields improved predictive performance compared to the Code-based Embedding, CodeEmb, and makes it possible to train models on differently formatted EHR data interchangeably due to its code-agnostic nature.

We test our framework on two EHR datasets, the Medical Information Mart for Intensive Care (MIMIC-III) (Johnson et al., 2016) and eICU Collaborative Research Database (Pollard et al., 2018), which use completely different medical code systems. Based on extensive experiments using five prediction tasks under diverse settings (e.g. standard single-domain learning, zero-shot and few-shot transfer learning, pooled learning), the best model of DescEmb demonstrates superior or comparable performance to the best model of CodeEmb in the vast ma-

jority of cases, outperforming by an average of 2.6% P AUPRC.

The main contributions of our work can be summarized as follows:

- 1. DescEmb achieves comparable or superior performance to CodeEmb on a comprehensive set of common clinical predictive tasks. Detailed results can be found in Table 1, 2.
- 2. Two differently structured EHR can be used to train and test predictive models interchangeably while rarely sacrificing model performance, often showing higher performance than when training on a single EHR. Visualized results can be found in Figure 4.
- 3. Two differently structured EHR can be pooled into one dataset and trained jointly with a description-based representation without the need for additional preprocessing or domain knowledge. For the result, refer to Table 3.
- 4. DescEmb shows notable performance in overall experiments, opening the door to a text-based approach in predictive healthcare research that is not constrained by EHR structure nor special domain knowledge.

2. Related Work

2.1. Neural Text Encoders

Early text embedders encode each word in a vocabulary as a vector whose semantic similarity to other words is represented by a distance measure (e.g. cosine similarity), or distribution of words (Mikolov et al., 2013; Pennington et al., 2014). Recently, Bidirectional Encoder Representations from Transformers (BERT) and its variants (Devlin et al., 2019; Lan et al., 2019; Liu et al., 2019; Yang et al., 2019) have shown improvements on various tasks in natural language processing (NLP). They employ a pre-training strategy, Masked Language Modeling (MLM) and Next Sentence Prediction (NSP), to learn contextual text representations that incorporates the complex relationships within the input text.

In the biomedical domain, several studies have developed BERT variants further trained on medical or clinical corpora. These studies have continually pre-trained their models on research articles from PubMed (Lee et al., 2019), MIMIC-III clinical text (Alsentzer et al., 2019), or a combination of the two (Peng et al., 2019), and scratch trained on articles from PubMed (Gu et al., 2020).

2.2. Representation Learning for Predictive Healthcare

Predictive models with EHR data use various architectures such as autoencoders (Miotto et al., 2016; Che et al., 2015) and recurrent neural networks (RNN) (Lipton et al., 2015; Choi et al., 2016b,a). Other model architectures are also used for predictive healthcare such as gradient boosted machines (Chen et al., 2019), convolutional nets (Nguyen et al., 2016; Landi et al., 2020), and Transformer-based models (Song et al., 2018; Shang et al., 2019; Choi et al., 2020).

Previous research approaches are focused on codebased embedding. Our paper deals with the unification of heterogeneous code systems in EHR—and therefore sits independent to these previous works. As such, our proposed approach can be combined with prior frameworks.

3. Methods

3.1. Datasets

We draw on two large, publicly available datasets: the Medical Information Mart for Intensive Care III (MIMIC-III) (Johnson et al., 2016), and the eICU Collaborative Research Database (eICU) (Pollard et al., 2018). MIMIC-III includes all patients admitted to the intensive care unit (ICU) at Beth Israel Deaconess Medical Center from 2001 to 2012, and contains over 60,000 unique ICU stays with millions of observations. The eICU Collaborative Research Database is a multi-center database comprised of deidentified health data associated with over 200,000 ICU stays across the United States between 2014-2015.

Both MIMIC-III and eICU contain time-stamped records of medical events such as labs, medications, and drug inputs for each patient stay. MIMIC-III and eICU are recorded based on completely different code structures throughout the data. For example, the clinical concept "an infusion event of nitroglycerin" is represented in eICU as the string "Nitroglycerin (mcg/min)". However, the same semantic concept would be represented in MIMIC-III using the in-house item ID 222056 (a Metavision code, for "Nitroglycerin"); item ID 30049 (a CareVue code, for "Nitroglycerin"); or item ID 30121 (a CareVue code, for "Nitroglycerin-k"). The same goes for all medical events including diagnosis, medications, labs, etc. Consequently, we aggregate descriptions and values for comparability between formats and do not perform any within-code string manipulation. Detailed data preprocessing is provided in Appendix C.

3.2. Structure of Electronic Health Records

In this section, we describe the structure of EHR and introduce the notations to be used throughout the paper. Let p^i denote the i-th patient in the EHR data. As our problem setting is focused on individual patients, we drop the superscript when clear. A single patient p can be seen as a series of medical events (c_1, c_2, \ldots, c_T) for $c_i \in \mathcal{C}$ where \mathcal{C} denotes the set of all medical events such as diagnoses or prescriptions. Each event c_i is typically timestamped, giving us the sequence of time information (t_1, t_2, \ldots, t_T) .

A single medical event c_i is often associated with a text description. For example, if c_i were a prescription event, it could be accompanied by the medication name (e.g. "Aspirin 300mg Tab."). If it were a diagnosis event, it could come with an ICD-9 code (e.g. 401.9), which in turn has its own description ("Unspecified essential hypertension"). We use d_i to denote this text description, which consists of a se-




Figure 2: DescEmb model framework. On the top, the patient timeline from the ICU admission is represented as a line. Each dot on the line is a code c_i which can be any medical event. Each code c_i can be converted to its own description d_i . The neural text encoder B_{ϕ} accepts the description d_i and produces its latent representation z_i . Given all z_1, z_2, \ldots, z_T , the predictive model P_{θ} predicts the outcome \hat{y} .

quence of words (or sub-words) $(w_{i,1}, w_{i,2}, \dots, w_{i,n})$ for $w_{i,j} \in \mathcal{W}$ where \mathcal{W} is the entire vocabulary.

Typically, two different medical institutions employ different C's, such as when one hospital uses ICD-9 diagnosis codes while another uses SNOMED diagnosis codes. The vocabulary \mathcal{W} , however, is the same for all hospitals as long as they use the same language. We propose DescEmb, a new framework for predictive healthcare, based on this observation.

3.3. Model Architecture

Previous deep learning predictive models for EHR data typically have an embedding layer (or a lookup table) E_{ψ} with trainable parameters ψ , which converts a single medical event c_i to its corresponding vector representation $\mathbf{c}_i \in \mathbb{R}^a$ where a is the dimension size. Instead of directly converting c_1, \ldots, c_T to c_1, \ldots, c_T with a trainable lookup table, DescEmb derives the latent representation of c_i , denoted as \mathbf{z}_i , based on its text description d_i . We feed d_i to the shared text encoder, B_{ϕ} , to obtain the description representations, $\mathbf{z}_i \in \mathbb{R}^b$ where b is the output dimension. Repeating this for all events in the given patient p, we can obtain a sequence of contextualized medical event representations $(\mathbf{z}_1, \mathbf{z}_2, \ldots, \mathbf{z}_T)$, which in turn is given to the prediction layer P_{θ} (e.g. RNN) with trainable parameters θ to make a prediction \hat{y}

(Fig 2.) The entire process of DescEmb can be summarized as below, with comparison to CodeEmb.

Given a patient record $p = (c_1, c_2, \dots, c_T)$,

 $Code\mbox{-}based\ Embedding:$

$$c_i = E_{\psi}(c_i)$$

$$\hat{y} = P_{\theta}(c_1, c_2, \dots, c_T)$$
(1)

Description-based Embedding:

$$d_i = (w_{i,1}, w_{i,2}, \dots, w_{i,n})$$

$$\boldsymbol{z}_i = B_{\phi}(d_i)$$

$$\hat{y} = P_{\theta}(\boldsymbol{z}_1, \boldsymbol{z}_2, \dots, \boldsymbol{z}_T)$$
(2)

3.4. Text Encoder

The text encoder B_{ϕ} in DescEmb can be any model that can generate a representation z_i from a given description d_i . We tested two model architectures for the text encoder: Bi-Directional Recurrent Neural Networks (Bi-RNN) and Bidirectional Encoder Representations from Transformers (BERT). For Bi-RNN, we derived the z_i by concatenating the last hidden states from each direction. For BERT, we used the output vector from the [CLS] token as z_i . We conducted experiments on different sizes of models that are pre-trained on a massive amount of general text such as Bert-tiny (2-layers), Bert-mini (4-layers), Bert-small (4-layers), Bert-base (12-layers).




Figure 3: Various methods of incorporating numeric values. We introduce four value embedding methods to represent both the code descriptions and the associated numeric values (e.g. "10" in "Tylenol 10 tabs").

We also conducted experiments on BERTs that are pre-trained on clinical text, such as BioBERT (Lee et al., 2019), ClinicalBERT (Alsentzer et al., 2019), and BlueBERT (Peng et al., 2019). We compared these models with BERTs that are pre-trained on the general domain. (results can be found in Appendix A). Moreover, we further pre-trained the text encoder on our dataset using Masked Language Modeling (MLM), following the original BERT procedure, to better fit the text encoder to our dataset. We did not include values during MLM since predicting values from descriptions is meaningless considering the various patient statuses.

3.5. Value Embedding

In the context of drug prescriptions, dosage or rate of infusion can be useful information to represent the patient's status. Hence, values incorporated in a code description provide rich informative features, potentially leading to an increased predictive performance. When using DescEmb, both the code description d_i and the associated numeric values can be embedded with the text encoder B_{ϕ} .

As shown in Figure 3, we introduce four different value embedding methods. First, Value Aggregation (VA) stands for aggregating the code description and the numeric values together as text. In this setting, because the BERT tokenizer recognizes each value as

a word, it sometimes tokenizes a given value in an unnatural way. For example, a number '1351' can be split into two sub-words '13' and '51', which does not best reflect the underlying meaning of the number. Hence, we additionally propose Digit-Split Value Aggregation (DSVA), where we split all numeric values into each digit first, then aggregate with the code description as text. In this way, a number is always tokenized into single digits, but the model still does not consider the place value. For instance, a number '1351' will be tokenized into '1', '3', '5', '1'; the model recognizes the first '1' and the last '1' as the same token even though the first '1' represents the thousandth place and the last '1' represents the first place. To mitigate this misunderstanding, we add learnable Digit Place Embedding (DPE) to every digit token indicating its place value, named Digit-Split Value Aggregation + Digit Place Embedding (DSVA+DPE). No further preprocessing was applied for unit measurements such as percent sign (%), mg, ml, and so on. This can only be applied to a model exploiting a neural text encoder which can add additional value embeddings for each digit. Value Concatenated (VC) embeds description and values separately. Similar to the other embedding methods, code descriptions and units of measurement are embedded through the text encoder, while values are passed through additional

Table 1: AUPRC of CodeEmbs and DescEmbs in prediction tasks for eIC	Table 1: AUPRO	of CodeEmbs ar	nd DescEmbs in	prediction	tasks for eICl
---	----------------	----------------	----------------	------------	----------------

	Model	Code	eEmb				scEmb		
	Woder	Code	Elilo		BE	RT		R	.NN
Task	Value Embedding	RD	W2V	CLS-FT	FT	Scr	FT + MLM	Scr	Scr + MLM
	VA	0.447	0.433	0.501	0.574	0.547	0.586	0.586	0.582
$\mathbf{D}\mathbf{x}$	DSVA	0.447	0.433	0.498	0.591	0.567	0.601	0.593	0.584
Dx	DSVA+DPE	-	-	_	0.594	0.571	0.602	0.594	0.583
	VC	0.562	0.549	0.557	0.562	0.546	0.555	0.557	0.557
	VA	0.112	0.153	0.209	0.177	0.17	0.216	0.237†	0.271
Mort	DSVA	0.112	0.153	0.209	0.223	0.215	0.213	0.235	0.247
Mort	DSVA+DPE	-	-	_	0.224	0.213	0.217	0.252	0.259
	VC	$0.24\dagger$	$0.239\dagger$	0.238†	$0.23\dagger$	$0.23\dagger$	0.223	0.237†	$0.227\dagger$
	VA	0.47†	0.439	0.533	0.52	0.511	0.514	0.537	0.539
$_{ m LOS>3}$	DSVA	$0.47\dagger$	0.439	0.529	0.53	0.538	0.529	0.539	0.537
LUS>3	DSVA+DPE	-	-	_	0.536	0.537	0.529	0.54	0.537
	VC	0.525	0.525	0.528	0.523	0.524	0.523	0.526	0.53
	VA	0.157	0.184	0.225	0.196†	0.185	0.196	0.224	0.237
$_{ m LOS>7}$	DSVA	0.157	0.184	0.225	0.216	0.222	0.221	0.227	0.233
LU3>1	DSVA+DPE	-	-	-	0.22	0.219	0.221	0.231	0.234
	VC	0.231	0.228	0.229	0.216	0.218	0.218	0.222	0.224
	VA	0.168	0.15	0.208	0.283	0.205	0.283	0.269	0.279
ReAdm	DSVA	0.168	0.15	0.206	0.284	0.264	0.29	0.28	0.275
neAum	DSVA+DPE	-	-	-	$0.289\dagger$	0.263	0.284	0.28	0.255
	VC	$0.217\dagger$	$0.183\dagger$	0.194	0.272	0.256	0.267	0.277	0.276

 \dagger : standard deviation > 0.02

Multi-Layer Perceptron (MLP) which yields an embedding vector for the values. These two embeddings are finally concatenated and work as a description representation z_i for input of the predictive model.

3.6. Model Optimization

Both CodeEmb and DescEmb are used for prediction, therefore we can use any typical prediction loss function \mathcal{L} such as the cross-entropy loss or mean squared error. For DescEmb, training an entire BERT-like text encoder B_{ϕ} while optimizing predictive model P_{θ} requires a significant amount of time and compute resources, which are often inaccessible by small hospitals. Therefore, we propose the following lightweight DescEmb method, CLS-finetune. The objective functions of each model are shown below.

Code-based Embedding
$$\underset{\theta,\psi}{\operatorname{argmin}} \mathcal{L}(y,\hat{y})$$
 (3)

Description-based Embedding $\underset{\theta,\phi}{\operatorname{argmin}} \mathcal{L}(y,\hat{y})$ (4)

DescEmb CLS-finetune $\underset{\theta,z_{CLS}}{\operatorname{argmin}} \mathcal{L}(y,\hat{y})$ (5)

CLS-finetune, as written in Eq. 5, keeps ϕ of the text encoder fixed but allows for fine-tuning only the medical event embeddings z_{CLS} derived from B. This can also be seen as initializing the parameters

of the embedding layer E_{ψ} with the values of z_{CLS} , instead of initializing with random values. CLS-finetune does not solely rely on B's ability to derive medical event embeddings, but allows flexibility for the model to adapt to given prediction task with reasonable computation overhead.

4. Results

4.1. Prediction Performance

To assess the general efficacy of the DescEmb framework, we evaluate both DescEmbs and CodeEmbs across five medical prediction tasks using two separate datasets. The results are in Table 1 and Table 2. Value embedding methods are abbreviated as explained in the method section. The results for DSVA + DPE in CodeEmb and CLS-FT are blank since they cannot use Digit Place Embedding. In CodeEmb, 'RD' represents a randomly initialized embedding layer while 'W2V' represents Word2Vec, a pre-training strategy for CodeEmb embedding layer (Mikolov et al., 2013). 'FT' stands for fine-tuning where we employ existing pre-trained BERT parameters and fine-tune them for the downstream tasks. 'Scr' stands for training from scratch where we do

Table 2: AUPRC of CodeEmb and DescEmb in prediction tasks for MIMIC-III.

		Code	Emple			Des	cEmb		
		Code	EIIIO		BE	RT		R	NN
Task	Value Embedding	RD	W2V	CLS-FT	FT	Scr	FT + MLM	Scr	Scr + MLM
	VA	0.726	0.704	0.733	0.76	0.747	0.767	0.767	0.762
$\mathbf{D}\mathbf{x}$	DSVA	0.726	0.704	0.731	0.77	0.752	0.776	0.77	0.766
DX	DSVA+DPE	-	-	-	0.771	0.752	0.764	0.768	0.763
	VC	0.757	0.751	0.752	0.756	0.745	0.75	0.755	0.753
	VA	0.228	0.209	0.346	0.343†	0.31	0.38	0.383	0.398
Mort	DSVA	0.228	0.209	0.347	0.377	0.378	0.379	$0.394\dagger$	0.39
Mort	DSVA+DPE	-	-	-	0.378	0.372	0.383	0.4	0.393
	VC	$0.313\dagger$	0.334	0.339	$0.336\dagger$	$0.335\dagger$	0.376	$0.344\dagger$	0.338
-	VA	0.582	0.585	0.608	0.616	0.601	0.616	0.624	0.63
$_{ m LOS>3}$	DSVA	0.582	0.585	0.608	0.624	0.617	0.619	0.631	0.632
LU3>3	DSVA +DPE	-	-	-	0.624	0.616	0.622	0.634	0.628
	VC	0.61	0.614	0.616	0.61	0.614	0.612	0.622	0.622
	VA	0.269	0.251	0.346	0.338	0.325	0.342	0.349	0.349
$_{ m LOS>7}$	DSVA	0.269	0.251	0.348	0.355	0.359	0.356	0.35	0.35
LUS>1	DSVA+DPE	-	-	-	0.36	0.359	0.353	0.352	0.353
	VC	0.326	0.342	0.346	0.341	0.339	0.344	0.347	0.352
-	VA	0.044	0.043	0.042	0.042	$0.045\dagger$	0.044	0.044	0.043
ReAdm	DSVA	0.044	0.043	0.041	0.043	$0.046\dagger$	0.044	0.045	0.044
neAum	DSVA+DPE	-	-	-	0.043	0.047	0.044	0.041	0.044
	VC	0.043	0.043	0.044	0.045	0.047	0.044	0.044	0.044

 \dagger : standard deviation > 0.02

not bring the pre-trained BERT but randomly initialize the model. 'FT + MLM' is a model that brings a pre-trained model and conducts Masked Language Modeling (MLM) on our dataset after which it is fine-tuned on downstream tasks. 'Scr + MLM' is similar to 'FT + MLM' but it does not bring the pre-trained model parameter. We utilize the BERT-Tiny architecture for the BERT-based text encoder because there was no significant performance difference among BERT variants across sizes and pre-training techniques specific to clinical domain corpus; detailed results on this part can be found in Appendix A.

DescEmb models achieve comparable or superior performance to CodeEmb on nearly every task across all value embedding methods at an average of 8%P with 12%P at maximum. Within DescEmb models, BERT-FT generally outperforms BERT-Scratch, verifying the effectiveness of pre-training on massive text corpus. Using the additional Masked Language Modeling (MLM) on our dataset marginally improved performance (+0.3%P AUPRC) for BERT models. We further test the efficacy of MLM in the transfer learning setting below. Of note, a Bi-RNN text encoder generally performs better than BERT-based models. We speculate that, since the maximum lengths of sub-tokens for one code description are 46 and 48

for MIMIC-III and eICU respectively, a simple and light-weighted text encoder model, in this case Bi-RNN, has enough capacity to grasp the features of descriptions. In other words, a large and complex model, in this case BERT, might be an excessively powerful tool to compute refined representations in our setting. We further analyzed factors that influence the most to the prediction, and found that CodeEmb and DescEmb share the same important features under the same task. Detailed results can be found in Appendix E.

Note that CLS-finetune in DescEmb, which requires the same amount of compute and time as CodeEmb but initializes the embeddings with the CLS outputs from pre-trained BERT, outperforms CodeEmb in nearly all cases. This demonstrates that there is ground to be gained by adopting description-based embedding compared to the classical codebased embedding. We also pre-train the CodeEmb's embedding layer in Word2Vec manner to have a fair comparison with the pre-trained DescEmb models. We observe that Word2Vec results are highly unstable, which sometimes underperform 3.4%P at the worst compared to randomly initialized CodeEmb. This result implies that pre-training at code-level is insufficient to fully capture the semantics of each code




Figure 4: Transfer learning performance (Top: MIMIC-III to eICU, Bottom: eICU to MIMIC-III). The X-axis is the portion of the target dataset used for transfer learning, and the Y-axis is the AUPRC at test time on the target dataset. Shading represents the standard deviation from ten seed experiments.

and sometimes harms the performance. On the other hand, all pre-trained DescEmb models consistently show high performance across all scenarios, verifying the robustness of pre-training at description-level.

For value embeddings, there is a large discrepancy between CodeEmbs and DescEmbs in Value Aggregation (VA) and Digit-Split Value Aggregation (DSVA) compared to other value embedding methods. We conjecture the underlying reason is that in VA and DSVA, the unique number of codes for CodeEmb explodes since a new code is needed when different values are used. This raises the curse of dimensionality. On the contrary, the unique number of subtokens used in DescEmb does not change significantly in either setting, resulting in a stable performance. Hence, DescEmb is a suitable model architecture for understanding values because it does not require creating a new code for different values. Value Concatenated (VC) performs the best in CodeEmb. In DescEmb, Digit-Split Value Aggregation with Digit Place Embedding (DSVA+DPE) shows higher performance on the whole than other value embedding methods. It suggests that the model has better numeric understanding since DPE explicitly notifies the model about the place value. For further experiments, we choose CodeEmb RD, FT-BERT, SC- RNN, SC-RNN + MLM, with VC for CodeEmb and DSVA+DPE for the DescEmb models.

4.2. Zero-Shot Transfer and Few-Shot Transfer

Because DescEmb's embedding space is determined not by a specific code structure, but rather by the language of the underlying text descriptions, our framework lends itself naturally to transfer learning across all hospitals regardless of their EHR format. On the other hand, in order to deploy a code-based model on a target dataset with a different code structure than the source dataset, the new code embeddings received by the predictive layer must be randomly initialized, as E_{ψ} is not shared between hospitals. Consequently, CodeEmb's zero-shot transfer can rely only on the predictive layer parameters whereas DescEmb allows additional flexibility by relying on the B_{ϕ} parameters. Here, we transfer one CodeEmb model and three DescEmb models: RD, FT-BERT, SC-RNN, and SC-RNN+MLM trained on the MIMIC-III to eICU dataset and vice versa on zero shot and multiple few shot ratios. For SC-RNN+MLM, we did not conduct additional MLM on the target dataset before the transfer. The results are shown in Figure 4.

Table 3: AUPRC of the models on the five prediction tasks in the three scenarios: single domain learning, transfer learning, pooled learning. We compared the AUPRC of code-based embedding model (CodeEmb), pre-trained BERT model (FT-BERT), RNN model (SC-RNN), and RNN model pre-trained on Masked Language Modeling (SC-RNN+MLM). Based on a t-test, a statistically meaningful increase and decrease against "Single" is marked with boldface and underline, respectively.

Task	Model	Single MIMIC-III	Transfer eICU	Pooled MIMIC-III	Single eICU	Transfer MIMIC-III	Pooled eICU
lask	Model		$\rightarrow \text{MIMIC-III}$			$\rightarrow \mathrm{eICU}$	
	CodeEmb	0.757	0.752**	0.755	0.562	0.558	0.563
$\mathbf{D}\mathbf{x}$	FT-BERT	0.771	0.775*	0.777*	0.594	0.608**	0.611*
Dx	SC-RNN	0.768	0.762	0.773**	0.594	0.602**	0.589
	SC-RNN+MLM	0.763	0.76	0.768	0.583	0.586	0.595*
	CodeEmb	0.313	0.313	0.313	0.24	0.233	0.247
Mort	FT-BERT	0.378	0.378	0.376	0.224	0.246*	0.248*
Mort	SC-RNN	0.4	0.385	0.401	0.252	0.267*	0.252
	SC-RNN+MLM	0.393	0.383	0.402	0.259	0.263	0.253
	CodeEmb	0.61	0.606	0.611	0.525	0.531	0.534*
$_{ m LOS>3}$	FT-BERT	0.624	0.628*	0.624	0.536	0.542*	0.549*
LOS>3	SC-RNN	0.634	0.632	0.63	0.54	0.543	0.549*
	SC-RNN+MLM	0.628	0.627	0.638*	0.537	0.541	0.548*
	CodeEmb	0.326	0.333	0.334	0.233	0.235	0.239*
$_{ m LOS>7}$	FT-BERT	0.36	0.356	0.354	0.22	0.230*	0.242**
LUS>1	SC-RNN	0.352	0.345	0.35	0.229	0.236*	0.253**
	SC-RNN+MLM	0.353	0.342	0.342	0.234	0.235	0.239*
	CodeEmb	0.043	0.044	0.049	0.217	0.218	0.232*
ReAdm	FT-BERT	0.043	0.044	0.051	0.289	0.274*	0.281
HEAUIII	SC-RNN	0.041	0.045	0.046	0.28	0.263	0.279
	SC-RNN+MLM	0.044	0.044	0.044	0.255	0.255	0.275*


^{*:} p value < 0.05, **: p value < 0.01

We observe predominantly higher performance of DescEmb over CodeEmb in both the zero-shot and few-shot transfer setting. When this is the case (that is, for all tasks except readmission prediction), DescEmb gains a particular advantage in zero-shot and smaller few-shot ratio transfer learnings, especially for the length-of-stay prediction tasks. This implies that DescEmb can be transferred to different hospitals while retaining its performance even for hospitals with a very small amount of data. We may intuitively understand these results as the uphill battle faced by the CodeEmb to adjust to a completely unfamiliar set of code embeddings—a disadvantage alleviated by a text-based framework and consequently not shared by DescEmb's predictive layer. Even with a very limited amount of (or no) fine-tuning data from the target dataset, DescEmb can use its knowledge of a prior dataset's text descriptions to generate effective embeddings at the outset.

4.3. Pooled Learning with Distinct EHR Formats

If we were to deploy a large-scale predictive model in reality, it is more likely that a single central server would pool EHR data from multiple institutions and train a large-scale deep learning model, rather than training many models from individual institutions and performing transfer learning when necessary. Such pooled learning presents an opportunity to train a single model to jointly learn information from all institutions. Applying CodeEmb to pooled learning, however, requires either substantial effort to unify code systems (if possible) or relinquishing control over the code vocabulary. Therefore, there is limited benefit of pooled learning for CodeEmb since it consumes a substantial amount of time and labor. Conversely, given that DescEmb is not restricted by specific code structures, pooling datasets does not require any further preprocessing nor extra investment of time and money.

In order to confirm the efficacy of DescEmb in the pooled learning scenario, we trained both De-



[For Dx, yellow dots include all labels in MIMIC-III dataset blue dots include all labels in eICU dataset]

Figure 5: PCA visualizations of the ICU representations from the two datasets. The X-axis and Y-axis correspond to two different principal components. Each dot represents one ICU stay, and the dot color represents the target label for binary classification tasks. For the diagnosis prediction task (Dx), labels could not be succinctly annotated due to its multi-label classification nature. Thus, we distinguish dataset sources by color: yellow being MIMIC-III and blue being eICU.

scEmb and CodeEmb on the pooled training set from both MIMIC-III and eICU, and tested on the individual test set. The results are reported in Table 3, where we compare model performance across various scenarios: train then evaluate on each dataset ("Single MIMIC-III" and "Single eICU"), train on one dataset then fine-tune and evaluate on another dataset ("Transfer eICU \rightarrow MIMIC-III" and "Transfer MIMIC-III \rightarrow eICU"), and train on the pooled dataset then evaluate on each dataset ("Pooled MIMIC-III" and "Pooled eICU"). We include both "Single" and "Transfer", both of which require individual model training on each dataset, to highlight the operational efficiency of pooled learning, which only requires a single model training on the pooled dataset.

Within pooled learning, DescEmb outperformed CodeEmb in all cases (8.9%P at most) except for readmission prediction for MIMIC-III, which indicates that DescEmb is clearly a more suitable framework for pooled learning. Of note, DescEmb's pooled training showed favorable results compared to the single domain setting as well as transfer learning setting for both MIMIC-III and eICU (more so for eICU which we analyze below). This indicates the efficiency of pooled learning with DescEmb on MIMIC-III and eICU, where only a single model needs to be trained and maintained, instead of training or transferring individual models for each dataset. Thanks to this efficiency, we believe DescEmb can open new doors for large-scale predictive models in terms of operational cost in finance and time.

4.4. Representation Distribution and Pooled Learning Advantages

From Table 3, we can see that eICU generally gained more performance increase than MIMIC-III from both pooled learning and transfer learning. We hypothesize that this comes from the data distribution properties of the two datasets. In order to confirm our hypothesis, we conducted Principal Component Analysis (PCA) on the ICU stay representation vectors obtained from the prediction model (the last hidden layer of the RNN) trained on the pooled dataset. The results in 5 show that, for some tasks, the eICU representations are distributed inside the MIMIC-III representation distributions, especially in LOS tasks where eICU gained notable performance increase from transfer and pooled learning compared to the single-domain learning. We deduce that the performance increase comes from learning a more generally distributed dataset, in this case MIMIC-III.

5. Conclusion

In this work we introduced a new predictive modeling framework for EHR, namely the description-based embedding (DescEmb), which unifies heterogeneous code systems by deriving the medical code embeddings with a neural text encoder. In a series of experiments with two public EHR datasets and five ICU-based prediction tasks, we demonstrated DescEmb's outperformance of CodeEmb. We also showed improved zero-shot and few-shot transfer learning performance thanks to the code-agnostic nature of De-

scEmb. Lastly, we showed that DescEmb provides operational efficiency by enabling us to train a single unified predictive model based on MIMIC-III and eICU, rather than training separate models for each EHR system. We believe this new framework will launch a new discussion around large-scale model training for EHR. Similar to BERT, which has been pre-trained on large text corpus and shown its robustness on text-based tasks, future work includes constructing a large scale EHR pre-trained model through unifying and pooling various hospitals in heterogeneous systems. This pre-trained model can be applied to any time-series EHR dataset without going through laborious pre-processing, which is costeffective for engineers. Also, incorporating additional modalities such as clinical notes or radiology images can be a key direction for future work.

Institutional Review Board (IRB)

This research does not require IRB approval.

Acknowledgments

This work was supported by Institute of Information & Communications Technology Planning & Evaluation (IITP) grant (No.2019-0-00075, Artificial Intelligence Graduate School Program(KAIST)), Korea Medical Device Development Fund grant (Project Number: 1711138160, KMDF_PR_20200901_0097), funded by the Korean government (the Ministry of Science and ICT, the Ministry of Trade, Industry and Energy, the Ministry of Health & Welfare, the Ministry of Food and Drug Safety).

References

- Emily Alsentzer, John Murphy, William Boag, Wei-Hung Weng, Di Jindi, Tristan Naumann, and Matthew McDermott. Publicly available clinical BERT embeddings. In *Proceedings of the 2nd Clinical Natural Language Processing Workshop*, pages 72–78, Minneapolis, Minnesota, USA, June 2019. Association for Computational Linguistics. doi: 10.18653/v1/W19-1909. URL https://www.aclweb.org/anthology/W19-1909.
- Zhengping Che, David Kale, Wenzhe Li, Mohammad Taha Bahadori, and Yan Liu. Deep computational phenotyping. In *Proceedings of the 21th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining*, pages 507–516, 2015.
- David Chen, Sijia Liu, Paul Kingsbury, Sunghwan Sohn, Curtis B Storlie, Elizabeth B Habermann, James M Naessens, David W Larson, and Hongfang Liu. Deep learning and alternative learning strategies for retrospective real-world clinical data. NPJ digital medicine, 2(1):1–5, 2019.
- Edward Choi, Mohammad Taha Bahadori, Joshua A Kulas, Andy Schuetz, Walter F Stewart, and Jimeng Sun. Retain: An interpretable predictive model for healthcare using reverse time attention mechanism. arXiv preprint arXiv:1608.05745, 2016a.
- Edward Choi, Mohammad Taha Bahadori, Andy Schuetz, Walter F Stewart, and Jimeng Sun. Doctor ai: Predicting clinical events via recurrent neural networks. In *Machine learning for healthcare conference*, pages 301–318. PMLR, 2016b.
- Edward Choi, Zhen Xu, Yujia Li, Michael Dusenberry, Gerardo Flores, Emily Xue, and Andrew Dai. Learning the graphical structure of electronic health records with graph convolutional transformer. In *Proceedings of the AAAI Conference on Artificial Intelligence*, volume 34, pages 606–613, 2020.
- "Healthcare Cost and Utilization Project" (HCUP). Hcup clinical classifications software (ccs) for icd-9-cm, 2016.
- Jacob Devlin, Ming-Wei Chang, Kenton Lee, and Kristina Toutanova. BERT: Pre-training of deep

- bidirectional transformers for language understanding. In Proceedings of the 2019 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies, Volume 1 (Long and Short Papers), pages 4171–4186, Minneapolis, Minnesota, June 2019. Association for Computational Linguistics. doi: 10.18653/v1/N19-1423. URL https://www.aclweb.org/anthology/N19-1423.
- Yu Gu, Robert Tinn, Hao Cheng, Michael Lucas, Naoto Usuyama, Xiaodong Liu, Tristan Naumann, Jianfeng Gao, and Hoifung Poon. Domain-specific language model pretraining for biomedical natural language processing. arXiv preprint arXiv:2007.15779, 2020.
- Varun Gulshan, Lily Peng, Marc Coram, Martin C Stumpe, Derek Wu, Arunachalam Narayanaswamy, Subhashini Venugopalan, Kasumi Widner, Tom Madams, Jorge Cuadros, et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs. Jama, 316(22): 2402–2410, 2016.
- Alistair EW Johnson, Tom J Pollard, Lu Shen, Liwei H Lehman, Mengling Feng, Mohammad Ghassemi, Benjamin Moody, Peter Szolovits, Leo Anthony Celi, and Roger G Mark. Mimic-iii, a freely accessible critical care database. *Scientific data*, 3: 160035, 2016.
- Zhenzhong Lan, Mingda Chen, Sebastian Goodman, Kevin Gimpel, Piyush Sharma, and Radu Soricut. Albert: A lite bert for self-supervised learning of language representations. arXiv preprint arXiv:1909.11942, 2019.
- Isotta Landi, Benjamin S Glicksberg, Hao-Chih Lee, Sarah Cherng, Giulia Landi, Matteo Danieletto, Joel T Dudley, Cesare Furlanello, and Riccardo Miotto. Deep representation learning of electronic health records to unlock patient stratification at scale. NPJ digital medicine, 3(1):1–11, 2020.
- Jinhyuk Lee, Wonjin Yoon, Sungdong Kim, Donghyeon Kim, Sunkyu Kim, Chan Ho So, and Jaewoo Kang. BioBERT: a pre-trained biomedical language representation model for biomedical text mining. *Bioinformatics*, 09 2019. ISSN 1367-4803. doi: 10.1093/bioinformatics/btz682. URL https://doi.org/10.1093/bioinformatics/btz682.

- Zachary C Lipton, David C Kale, Charles Elkan, and Randall Wetzel. Learning to diagnose with lstm recurrent neural networks. arXiv preprint arXiv:1511.03677, 2015.
- Yinhan Liu, Myle Ott, Naman Goyal, Jingfei Du, Mandar Joshi, Danqi Chen, Omer Levy, Mike Lewis, Luke Zettlemoyer, and Veselin Stoyanov. Roberta: A robustly optimized bert pretraining approach. arXiv preprint arXiv:1907.11692, 2019.
- Tomas Mikolov, Kai Chen, Greg Corrado, and Jeffrey Dean. Efficient estimation of word representations in vector space. arXiv preprint arXiv:1301.3781, 2013.
- Riccardo Miotto, Li Li, Brian A Kidd, and Joel T Dudley. Deep patient: an unsupervised representation to predict the future of patients from the electronic health records. *Scientific reports*, 6(1): 1–10, 2016.
- Phuoc Nguyen, Truyen Tran, Nilmini Wickramasinghe, and Svetha Venkatesh. Deepr: a convolutional net for medical records. *IEEE journal of biomedical and health informatics*, 21(1):22–30, 2016.
- Yifan Peng, Shankai Yan, and Zhiyong Lu. Transfer learning in biomedical natural language processing: An evaluation of bert and elmo on ten benchmarking datasets. In *Proceedings of the 2019 Workshop on Biomedical Natural Language Processing (BioNLP 2019)*, pages 58–65, 2019.
- Jeffrey Pennington, Richard Socher, and Christopher D Manning. Glove: Global vectors for word representation. In *Proceedings of the 2014 conference on empirical methods in natural language processing (EMNLP)*, pages 1532–1543, 2014.
- Tom J Pollard, Alistair EW Johnson, Jesse D Raffa, Leo A Celi, Roger G Mark, and Omar Badawi. The eicu collaborative research database, a freely available multi-center database for critical care research. *Scientific data*, 5(1):1–13, 2018.
- Alvin Rajkomar, Eyal Oren, Kai Chen, Andrew M Dai, Nissan Hajaj, Michaela Hardt, Peter J Liu, Xiaobing Liu, Jake Marcus, Mimi Sun, et al. Scalable and accurate deep learning with electronic health records. *NPJ Digital Medicine*, 1(1):1–10, 2018.

- Nina Rank, Boris Pfahringer, Jörg Kempfert, Christof Stamm, Titus Kühne, Felix Schoenrath, Volkmar Falk, Carsten Eickhoff, and Alexander Meyer. Deep-learning-based real-time prediction of acute kidney injury outperforms human predictive performance. NPJ digital medicine, 3(1):1–12, 2020.
- Junyuan Shang, Tengfei Ma, Cao Xiao, and Jimeng Sun. Pre-training of graph augmented transformers for medication recommendation. arXiv preprint arXiv:1906.00346, 2019.
- Huan Song, Deepta Rajan, Jayaraman Thiagarajan, and Andreas Spanias. Attend and diagnose: Clinical time series analysis using attention models. In *Proceedings of the AAAI Conference on Artificial Intelligence*, volume 32, 2018.
- Zhilin Yang, Zihang Dai, Yiming Yang, Jaime Carbonell, Ruslan Salakhutdinov, and Quoc V Le. Xlnet: Generalized autoregressive pretraining for language understanding. arXiv preprint arXiv:1906.08237, 2019.

Appendix A. AUPRC Results from Pre-Trained Text Encoders with Different Sizes and Pre-Training Techniques

Table 4 and Table 5 show AUPRC results differing in the size of pre-trained BERTs (BERT-tiny, BERT-mini, BERT-small, BERT) and in the domainspecific pre-training techniques (Bio-BERT, Bio-Clinical-BERT, Blue-BERT) in eICU and MIMIC-III respectively. In this experiment, we tested CLS-FT and FT-BERT for verifying the effectiveness of the variants. From the table, there is no consistent performance tendency among different sizes of BERTs and pre-training techniques across tasks and models with very marginal performance differences. Of note, large text encoders generally underperform smaller sizes of BERT. Contrary to our expectation, domainspecialized pre-training techniques rather harm the model performance compared to smaller sizes of BERTs. Overall, the size of the text encoder influences the performance greatly more than how pretraining techniques are modeled. For the experiments in the main paper, we choose BERT-tiny since it generally shows decent performance among other models and it requires less memory and computation time compared to the large models.

Appendix B. PCA Results for Varied Random Seeds

We show the PCA results while varying random seeds, which results in a differently split dataset. Figure 6 shows a similar result to Figure 5 in the main paper.

Appendix C. Detailed preprocessing method and table statistics

C.1. Detailed Preprocessing Information

In the following section we provide further detail about the construction of our datasets. As input for our predictive models, we employ three sources of information (we will further denote source of information as 'item' for simplicity)— laboratory, medication, and infusion—simultaneously for each patient. The .csv files corresponding to each item

are described in Table 6. Note that when merging MIMIC-III files 'INPUTEVENTS_MV' and 'IN-PUTEVENTS_CV', we remove 41 patient histories which straddle the transition between code systems and consequently are included partially in each file.

For the sake of comparability, we built patients cohorts from the full MIMIC-III and eICU databases based on the following criteria: (1) Medical ICU (MICU) patients (2) over the age of 18 who (3) remain in the ICU for over 12 hours. We operationalize criterion (1) in MIMIC-III as patients for whom the first care unit is the last care unit and ICU type is MICU (i.e. we exclude patients who have transferred ICUs). For patients with multiple ICU stays, we draw exclusively on the first stay, and we remove any ICU stays with fewer than 5 observed codes. Within each ICU stay, we restrict our sample to the first 150 codes during the first 12 hours of data, and remove codes which occur fewer than 5 times in the entire dataset. Code sequence is determined by the associated time stamp.

C.2. Predictive Task Labels

We predict patient outcomes across five tasks: readmission, mortality, an ICU stay exceeding three or seven days, and diagnosis prediction. The first four are binary classification, the last multi-label. The variable-level criteria to generate these labels is available in Table 8.

In order to generate diagnosis labels for comparison across datasets, we employ the Clinical Classifications Software (CCS) for ICD-9-CM of the Health-care Cost and Utilization Project (Cost and , HCUP). We utilize the highest level representation available of ICD9 diagnosis, a common code format across EHR. There are 18 such representations. MIMIC-III and eICU diagnoses represented by ICD9 codes are simply mapped using the CCS classification. eICU ICD10 diagnoses are mapped first to ICD9 codes before to their CCS classification. Finally, for eICU string diagnoses (e.g. Infection ... | ... bacterial ... | ... tuberculosis), we first search the most granular level for a string match with ICD9 before proceeding up the hierarchy for a match.

C.3. Data Statistics

After preprocessing input data, we found that some patients lack all three items. Consequently, in some cases the item was left out from the patient dataset. For example, some patients have all the items in the

Table 4: Results of BERT variation models on eICU

Task	Model	BERT-tiny	BERT-mini	BERT-small	BERT	Bio-BERT	Bio-clinical-BERT	Blue-BERT
Dx	CLS-FT	0.557	0.559	0.558	0.556	0.556	0.558	0.559
Dx	FT-BERT	0.594	0.595	0.595	0.591	0.59	0.593	0.591
Mort	CLS-FT	0.238	0.242	0.233	0.228	0.231	0.228	0.228
MOL	FT-BERT	0.224	0.223	0.22	0.219	0.219	0.215	0.216
LOS;3	CLS-FT	0.528	0.528	0.526	0.524	0.527	0.525	0.526
LOSES	FT-BERT	0.536	0.527	0.523	0.523	0.522	0.528	0.526
LOS;7	CLS-FT	0.229	0.233	0.228	0.222	0.223	0.226	0.228
LOSE	FT-BERT	0.22	0.218	0.215	0.214	0.213	0.217	0.215
ReAdm	CLS-FT	0.194	0.239	0.238	0.231	0.239	0.223	0.237
ReAdili	FT-BERT	0.289	0.283	0.278	0.276	0.277	0.281	0.275

Table 5: Results of BERT variation models on MIMIC-III

Task	Model	BERT-tiny	BERT-mini	BERT-small	BERT	Bio-BERT	Bio-clinical-BERT	Blue-BERT
Dx	CLS-FT	0.752	0.754	0.755	0.757	0.755	0.755	0.754
Dx	FT-BERT	0.771	0.77	0.77	0.767	0.769	0.769	0.767
Mort	CLS-FT	0.339	0.345	0.34	0.344	0.339	0.338	0.335
WIOI	FT-BERT	0.378	0.371	0.365	0.362	0.363	0.363	0.364
I OG 12	CLS-FT	0.616	0.614	0.615	0.615	0.611	0.61	0.608
$LOS_{\ifomtle{i}{i}\end{substrate}3$	FT-BERT	0.624	0.623	0.623	0.621	0.626	0.622	0.62
LOS;7	CLS-FT	0.346	0.344	0.341	0.343	0.344	0.344	0.338
LOSE	FT-BERT	0.36	0.352	0.342	0.342	0.345	0.345	0.343
ReAdm	CLS-FT	0.044	0.043	0.044	0.045	0.044	0.045	0.044
IteAuIII	FT-BERT	0.043	0.043	0.044	0.043	0.045	0.043	0.043

Table 6: File sources for each dataset

Item	Source	Filename
Lab	MIMIC-III	LABEVENTS.csv
Lab	eICU	lab.csv
Med	MIMIC-III	PRESCRIPTIONS.csv
Med	eICU	medication.csv
Inf	MIMIC-III	INPUTEVENTS.csv
Inf	eICU	infusionDrug.csv

code sequence, while others are included without all of them. In the MIMIC-III and eICU we use, the size of the entire dataset is the same as the union shown in Table 7 for each of the source dataset.

C.4. Hyperparameters

We conducted the hyperparameter searching experiment in CodeEmb and DescEmb on MIMIC-III and eICU. We swept the hyperparameter space within a fixed range, presented below, by grid search.


- dropout = [0.1, 0.3, 0.5]
- \bullet embedding dimension = [128, 256, 512, 768]

Table 7: Prediction dataset summary statistics

Statistic	eICU	MIMIC-III
N Observations	12,818	18,536
N ICU Stays	12,818	18,536
N Hospital Adm.	12,818	18,536
N Patients	12,818	18,536
Mean Seq. Length	48.8	65.3
Median Seq. Length	43.0	57.0
N Total Codes	$625,\!594$	1,211,107
N Unique Codes	2,018	2,855

- hidden dimension = [128, 256, 512]
- learning rate = [5e-4, 1e-4, 5e-5, 1e-5]

We spent over 72 hours trying to find the best hyperparameter set for each case. We noticed that hyperparameters did not significantly affect the final result. For the experiment's simplicity, we unified one hyperparameter set for all cases without greatly harming each individual model's performance. The final set results are dropout of 0.3, embedding dimension and



[For Dx, yellow dots include all labels in MIMIC-III dataset blue dots include all labels in eICU dataset]

Figure 6: PCA visualizations on the ICU Representations for different random seeds.

Table 8: Specific label criteria

Target	eICU	MIMIC-III
Readmission	Count('patientUnitStayID') >1	Count('ICUSTAY_ID') >1
Mortality	'unitDischargeStatus'=='Expired'	'DOD_HOSP' not null
LOS > 3 Days	'unitDischargeOffset' >3*24*60	LOS > 3
LOS > 7 Days	'unitDischargeOffset' $>7*24*60$	LOS > 7
Diagnosis	set('diagnosisstring') per 1 ICU	ICD9_CODE-LONG_TITLE

hidden dimension for the predictive model as 128 and 256 respectively, and learning rate of 1e-4.

Appendix D. Case visualize in description embedding

In pooled dataset situation, we conducted PCA on all text descriptions and explored codes that contain 'hydrocortisone' with different unit of measurement and dosage, which are colored as red in Figure we attached. The result demonstrates that similar text descriptions with small variants of measurement and dosage are located close to each other. The descriptions for the above points are as follows. ['hydrocortisone pf iv push', 'hydrocortisone na succ. iv', 'hydrocortisone po/ng', 'hydrocortisone study drug *ind* iv', 'hydrocortisone cream 1% tp', 'hydrocortisone na succinate pf iv', 'hydrocortisone sod succinate iv', 'hydrocortisone po', 'hydrocortisone rectal 2.5% cream pr', 'hydrocortisone pf iv']




Figure 7: PCA visualizations on the representation of medication with suffix variation in pooled.




Figure 8: Top and bottom 20 features for "Disease of respiratory system" and "mortality" prediction model with DescEmb Scr-RNN.

Appendix E. Qualitative analysis for features importance in prediction

E.1. Top and bottom features for diagnosis and mortality prediction in DescEmb Scr-RNN model

We used the gradient of backpropagation of each feature; the larger the gradient, the more impactful the feature. Figure 8 shows the 20 features most and least contributing to the prediction for 'Disease for respiratory system' in diagnosis prediction (left two) and 'mortality' (right two) on MIMIC-III and eICU using DescEmb RNN-Scratch (further named as RNN-Scr). For 'Disease for respiratory system', we trained a new model to conduct the binary classification (respiratory system vs not respiratory system) instead of multi-label classification which was presented in the paper to better analyze the contributing features. In 'Disease for respiratory system', most influential factors were related to medication whereas in 'Mortality', most factors were a combination of medication and lab values. In 'Mortality', we noticed that medicines often prescribed to those close to death exist in the top 20.

E.2. Comparison of top features between different models in diagnosis prediction tasks

Tables 9, 10, 11, 12 show the most influential factors for five tasks (Disease of the nervous system and sense organs, Disease of circulatory system, Disease of digestive system, Disease of respiratory system) for DescEmb RNN-Scr, Bert-FT, and CodeEmb on MIMIC-III and eICU. In 'Disease of nervous system', it mainly contains medications that are consumed in the department of neurology. In 'Disease of Circulatory', there are diuretics ('furosemide') and machines that measure blood pressure. There also are blood transfusions, antithrombotic, antibiotic, and other heart medicines for those who had operations. For 'Disease of Respiratory', most of the factors are antibiotics utilized on pneumonia and lung injury. In 'Disease of Digestive', most factors are medicines prescribed for digestive and gastrointestinal inflammation. In conclusion, the top most influential features under each task are reasonable and are highly related to the given task. Also, most features are shared across models (DescEmb RNN-Scr, BERT-FT, and CodeEmb) and datasets (MIMIC-III and eICU).

Table 9: Top features for "Disease of the nervous system and sense organs" prediction models with DescEmb and CodeEmb

MIMIC-III	DescE		CodeEmb
	RNN-Scr	Bert-FT	RD
	latanoprost 0. 005 % ophth. soln. ou	artificial tear ointment ou	timolol maleate 0. 5 % both eyes
	1 1		ž.
	latanoprost 0. 005 % ophth. soln. left eye	brimonidine tartrate 0. 15 % ophth. os	carbamazepine
	pyridostigmine bromide po	latanoprost 0. 005 % ophth. soln. ou	carbidopa - levodopa cr 50 - 200 po
	erythromycin 0. 5 % ophth oint od	topiramate topamax po / ng	ropinirole
	latanoprost 0. 005 % ophth. soln. right eye	carbamazepine	topiramate topamax po
	carbidopa - levodopa cr 50 - 200 po	sumatriptan succinate sc	carbamazepine po / ng
	brimonidine tartrate 0. 15 % ophth. ou	erythromycin 0. 5 % ophth oint ou	ciprofloxacin 0. 3 % ophth soln both e
	gabapentin po	ciprofloxacin 0. 3 % ophth soln both eyes	sumatriptan succinate sc
	phenobarbital	timolol maleate 0. 25 % both eyes	oxcarbazepine po
	prazosin po	gabapentin po	erythromycin 0. 5 % ophth oint ou
	oxcarbazepine po	prazosin po	losartan potassium po / ng
	latanoprost 0. 005 % ophth. soln. both eyes	oxcarbazepine po	phenobarbital
	brimonidine tartrate 0. 15 % ophth. both eyes	ropinirole	lidocaine 1 % id
	carbamide peroxide 6. 5 % ad	latanoprost 0. 005 % ophth. soln. right eye	valproic acid
	artificial tears preserv. free both eyes	latanoprost 0. 005 % ophth. soln. both eyes	timolol maleate 0. 25 % both eyes
	topiramate po	brimonidine tartrate 0. 15 % ophth. ou	phenobarbital po
	hydromorphone - hp ivpca	pyridostigmine bromide po	ciprofloxacin 0. 3 % ophth soln both e
	carbamazepine	carbamide peroxide 6. 5 % ad	artificial tear ointment ou
	topiramate topamax po / ng	carbidopa - levodopa cr 50 - 200 po	topiramate topamax po / ng
	ropinirole	clozapine po	fluvoxamine maleate po
eICU	ropinirole	clozapine po	fluvoxamine maleate po
eicu			fluvoxamine maleate po
ICU	levetiracetam po	levetiracetam po	phenytoin
ICU	levetiracetam po phenytoin	levetiracetam po phenytoin	phenytoin lactulose oral
CU	levetiracetam po	levetiracetam po	phenytoin
ICU	levetiracetam po phenytoin	levetiracetam po phenytoin	phenytoin lactulose oral levetiracetam po phenytoin
ICU	levetiracetam po phenytoin lactulose oral	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral zolpidem tartrate oral	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven colace po	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb hydromorphone hcl intraven
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral zolpidem tartrate oral seroquel oral	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven colace po levetiracetam po	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb hydromorphone hel intraven phenylephrine mcg / kg / min
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral zolpidem tartrate oral seroquel oral naloxone hcl intraven	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven colace po levetiracetam po seroquel oral	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb hydromorphone hcl intraven phenylephrine mcg / kg / min naloxone hcl intraven
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral zolpidem tartrate oral seroquel oral naloxone hcl intraven levetiracetam po	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven colace po levetiracetam po seroquel oral restoril oral	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb hydromorphone hcl intraven phenylephrine mcg / kg / min naloxone hcl intraven seroquel oral
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral zolpidem tartrate oral seroquel oral naloxone hcl intraven levetiracetam po levetiracetam ivpb	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven colace po levetiracetam po seroquel oral restoril oral hydromorphone hcl intraven	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb hydromorphone hcl intraven phenylephrine mcg / kg / min naloxone hcl intraven
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral zolpidem tartrate oral seroquel oral naloxone hcl intraven levetiracetam po levetiracetam ivpb phenylephrine mcg / kg / min	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven colace po levetiracetam po seroquel oral restoril oral hydromorphone hcl intraven hydrochlorothiazide oral	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb hydromorphone hcl intraven phenylephrine mcg / kg / min naloxone hcl intraven seroquel oral restoril oral thiamine po
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral zolpidem tartrate oral seroquel oral naloxone hcl intraven levetiracetam po levetiracetam ivpb	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven colace po levetiracetam po seroquel oral restoril oral hydromorphone hcl intraven	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb hydromorphone hcl intraven phenylephrine mcg / kg / min naloxone hcl intraven seroquel oral restoril oral
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral zolpidem tartrate oral seroquel oral naloxone hcl intraven levetiracetam po levetiracetam ivpb phenylephrine mcg / kg / min	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven colace po levetiracetam po seroquel oral restoril oral hydromorphone hcl intraven hydrochlorothiazide oral	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb hydromorphone hel intraven phenylephrine mcg / kg / min naloxone hel intraven seroquel oral restoril oral thiamine po hydrochlorothiazide oral lorazepam
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral zolpidem tartrate oral seroquel oral naloxone hcl intraven levetiracetam po levetiracetam ivpb phenylephrine mcg / kg / min restoril oral	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven colace po levetiracetam po seroquel oral restoril oral hydromorphone hcl intraven hydrochlorothiazide oral naloxone hcl intraven phenylephrine mcg / kg / min lorazepam	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb hydromorphone hcl intraven phenylephrine mcg / kg / min naloxone hcl intraven seroquel oral restoril oral thiamine po hydrochlorothiazide oral
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral zolpidem tartrate oral seroquel oral naloxone hcl intraven levetiracetam po levetiracetam ivpb phenylephrine mcg / kg / min restoril oral hydromorphone hcl intraven	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven colace po levetiracetam po seroquel oral restoril oral hydromorphone hcl intraven hydrochlorothiazide oral naloxone hcl intraven phenylephrine mcg / kg / min lorazepam chlorhexidine gluconate mt	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb hydromorphone hel intraven phenylephrine mcg / kg / min naloxone hel intraven seroquel oral restoril oral thiamine po hydrochlorothiazide oral lorazepam
ICU	levetiracetam po phenytoin lactulose oral naloxone hcl intraven xanax po phenytoin lorazepam lactulose oral zolpidem tartrate oral seroquel oral naloxone hcl intraven levetiracetam po levetiracetam ivpb phenylephrine mcg / kg / min restoril oral hydromorphone hcl intraven thiamine po	levetiracetam po phenytoin levetiracetam ivpb levetiracetam po phenytoin lactulose oral xanax po naloxone hcl intraven colace po levetiracetam po seroquel oral restoril oral hydromorphone hcl intraven hydrochlorothiazide oral naloxone hcl intraven phenylephrine mcg / kg / min lorazepam	phenytoin lactulose oral levetiracetam po phenytoin zolpidem tartrate oral chlorhexidine gluconate mouth rinse levetiracetam po levetiracetam ivpb hydromorphone hel intraven phenylephrine mcg / kg / min naloxone hel intraven seroquel oral restoril oral thiamine po hydrochlorothiazide oral lorazepam midazolam versed iv

Table 10: Top features for "Disease of the circulatory system" prediction models with DescEmb and CodeEmb

MIMIC-III		Emb	CodeEmb
	RNN-Scr	Bert-FT	RD
	prazosin po	prazosin po	prazosin po
	500n / s 40meq k +	buprenorphine - naloxone 8mg - 2mg sl	enoxaparin lovenox
	xigris	enoxaparin lovenox	enoxaparin iovenox enema
	9	1	
	enema	howell - jolly bodies	reticulocyte count automated
	enoxaparin lovenox	500n / s 40meq k +	ethacrynate sodium iv
	wright giemsa	wright giemsa	fibersource hn full
	leucovorin calcium iv	reticulocyte count automated	enoxaparin lovenox
	wright giemsa	enema	levothyroxine sodium ng
	howell - jolly bodies	thrombosis	leucovorin calcium iv
	ethacrynate sodium iv	insulin - humalog	gray top hold plasma
	mexiletine po	cd23	carafate sucralfate
	buprenorphine - naloxone 8mg - 2mg sl	mexiletine po	xigris
	reticulocyte count automated	ethacrynate sodium iv	wright giemsa
	enema	fibersource hn full	thrombosis
	golytely	enoxaparin lovenox	carafate sucralfate
	thrombosis	thrombosis	nutren pulmonary
	iv piggyback	gray top hold plasma	amikacin
	gray top hold plasma	buprenorphine - naloxone 8mg - 2mg sl	macrophage
	carafate sucralfate	leucovorin calcium iv	mexiletine po
	insulin - humalog	macrophage	buprenorphine - naloxone 8mg - 2m
eICU			
	hydrochlorothiazide po	hydrochlorothiazide po	lipitor po
	hydrochlorothiazide po	hydrochlorothiazide po	lipitor po
	furosemide lasix intravenous	hydrochlorothiazide oral	hydrochlorothiazide po
	furosemide lasix intravenous hydrochlorothiazide oral	hydrochlorothiazide oral lipitor po	hydrochlorothiazide po coreg
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device	hydrochlorothiazide oral lipitor po furosemide lasix intravenous	hydrochlorothiazide po coreg amiodarone bolus ivpb
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg bumetanide	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg lovenox subcutan	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device alteplase iv
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg bumetanide catheter	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg lovenox subcutan digoxin oral	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device alteplase iv bumetanide
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg bumetanide catheter digoxin oral	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg lovenox subcutan digoxin oral amiodarone bolus ivpb	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device alteplase iv bumetanide lovenox subcutan
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg bumetanide catheter digoxin oral potassium phosphate dibasic iv	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg lovenox subcutan digoxin oral amiodarone bolus ivpb phenylephrine mcg / kg / min	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device alteplase iv bumetanide lovenox subcutan amiodarone bolus ivpb
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg bumetanide catheter digoxin oral potassium phosphate dibasic iv metoprolol tartrate per g tube	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg lovenox subcutan digoxin oral amiodarone bolus ivpb phenylephrine mcg / kg / min wbcs in body fluid	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device alteplase iv bumetanide lovenox subcutan amiodarone bolus ivpb wbcs in body fluid
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg bumetanide catheter digoxin oral potassium phosphate dibasic iv metoprolol tartrate per g tube amiodarone bolus ivpb	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg lovenox subcutan digoxin oral amiodarone bolus ivpb phenylephrine mcg / kg / min wbcs in body fluid potassium phosphate dibasic iv	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device alteplase iv bumetanide lovenox subcutan amiodarone bolus ivpb wbcs in body fluid metronidazole po
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg bumetanide catheter digoxin oral potassium phosphate dibasic iv metoprolol tartrate per g tube amiodarone bolus ivpb cefepime hcl intravenous	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg lovenox subcutan digoxin oral amiodarone bolus ivpb phenylephrine mcg / kg / min wbcs in body fluid potassium phosphate dibasic iv digoxin oral	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device alteplase iv bumetanide lovenox subcutan amiodarone bolus ivpb wbcs in body fluid metronidazole po digoxin oral
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg bumetanide catheter digoxin oral potassium phosphate dibasic iv metoprolol tartrate per g tube amiodarone bolus ivpb cefepime hcl intravenous lanoxin oral	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg lovenox subcutan digoxin oral amiodarone bolus ivpb phenylephrine mcg / kg / min wbcs in body fluid potassium phosphate dibasic iv digoxin oral furosemide device	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device alteplase iv bumetanide lovenox subcutan amiodarone bolus ivpb wbcs in body fluid metronidazole po digoxin oral lanoxin oral
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg bumetanide catheter digoxin oral potassium phosphate dibasic iv metoprolol tartrate per g tube amiodarone bolus ivpb cefepime hcl intravenous lanoxin oral atorvastatin calcium per ng tube	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg lovenox subcutan digoxin oral amiodarone bolus ivpb phenylephrine mcg / kg / min wbcs in body fluid potassium phosphate dibasic iv digoxin oral furosemide device lanoxin oral	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device alteplase iv bumetanide lovenox subcutan amiodarone bolus ivpb wbcs in body fluid metronidazole po digoxin oral lanoxin oral tylenol ng tube
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg bumetanide catheter digoxin oral potassium phosphate dibasic iv metoprolol tartrate per g tube amiodarone bolus ivpb cefepime hcl intravenous lanoxin oral atorvastatin calcium per ng tube tylenol ng tube	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg lovenox subcutan digoxin oral amiodarone bolus ivpb phenylephrine mcg / kg / min wbcs in body fluid potassium phosphate dibasic iv digoxin oral furosemide device lanoxin oral tylenol ng tube	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device alteplase iv bumetanide lovenox subcutan amiodarone bolus ivpb wbcs in body fluid metronidazole po digoxin oral lanoxin oral tylenol ng tube potassium phosphate dibasic iv
	furosemide lasix intravenous hydrochlorothiazide oral furosemide device lipitor po lovenox subcutan alteplase iv coreg bumetanide catheter digoxin oral potassium phosphate dibasic iv metoprolol tartrate per g tube amiodarone bolus ivpb cefepime hcl intravenous lanoxin oral atorvastatin calcium per ng tube	hydrochlorothiazide oral lipitor po furosemide lasix intravenous furosemide device alteplase iv bumetanide coreg lovenox subcutan digoxin oral amiodarone bolus ivpb phenylephrine mcg / kg / min wbcs in body fluid potassium phosphate dibasic iv digoxin oral furosemide device lanoxin oral	hydrochlorothiazide po coreg amiodarone bolus ivpb digoxin oral hydrochlorothiazide oral furosemide lasix intravenous furosemide device alteplase iv bumetanide lovenox subcutan amiodarone bolus ivpb wbcs in body fluid metronidazole po digoxin oral lanoxin oral tylenol ng tube

Table 11: Top features for "Disease of the respiratory system" prediction models with DescEmb and CodeEmb

MIMIC-III		DescEmb	CodeEmb
	RNN-Scr	Bert-FT	RD
	fluticasone – salmeterol	fluticasone - salmeterol diskus 100 / 50 ih	albuterol - ipratropium ih
	azithromycin	albuterol - ipratropium ih	fluticasone - salmeterol 100 / 50
	azithromycin ng	azithromycin	aztreonam
	fluticasone - salmeterol 100 / 50 ih	azithromycin ng	azithromycin po
	albuterol - ipratropium ih	levofloxacin po / ng	levofloxacin pb
	clozapine po / ng	tiotropium bromide ih	cefepime
	azithromycin po / ng	azithromycin po / ng	tiotropium bromide ih
	fluticasone - salmeterol 250 / 50 ih	azithromycin po	fluticasone - salmeterol 100 / 50
	ipratropium bromide mdi ih	fluticasone - salmeterol 100 / 50 ih	lansoprazole oral disintegrating t
	fluticasone propionate 110mcg ih	aztreonam	levofloxacin po / ng
	ipratropium bromide neb ih	clozapine po / ng	metronidazole po
	lansoprazole oral disintegrating	azithromycin po	levofloxacin
	tiotropium bromide ih	ipratropium bromide neb ih	azithromycin
	-		•
	levofloxacin po / ng	cefepime	azithromycin ng
	levofloxacin pb	fluticasone - salmeterol 250 / 50 ih	nutren pulmonary full
	levofloxacin	levofloxacin pb	ipratropium bromide mdi ih
	aztreonam	lansoprazole oral disintegrating tab	fluticasone propionate 110mcg i
	azithromycin po	levofloxacin	lansoprazole oral suspension ng
	cefepime	carafate sucralfate	tiotropium bromide ih
	lansoprazole oral	nutren pulmonary full	ipratropium bromide neb ih
ICU			
ICU	alteplase iv	cefepime hcl intravenous	alteplase iv
ICU	alteplase iv cefepime hcl intravenous	cefepime hcl intravenous furosemide device	alteplase iv
CU	cefepime hcl intravenous	•	cefepime hcl intravenous
CCU	-	furosemide device	*
CU	cefepime hcl intravenous metronidazole po levofloxacin po	furosemide device levofloxacin po alteplase iv	cefepime hcl intravenous pneumococcal im
CCU	cefepime hcl intravenous metronidazole po	furosemide device levofloxacin po alteplase iv lovenox subcutan	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl
CCU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin
CU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po
ICU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan levofloxacin furosemide device	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po aspirin chew tab ngt	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po hydromorphone hcl intraven
ICU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan levofloxacin	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po aspirin chew tab ngt hydromorphone hcl intraven	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po hydromorphone hcl intraven vancomycin in ivpb
CU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan levofloxacin furosemide device pneumococcal im albuterol sulfate inhl	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po aspirin chew tab ngt hydromorphone hcl intraven pneumococcal im	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po hydromorphone hcl intraven
CU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan levofloxacin furosemide device pneumococcal im albuterol sulfate inhl alteplase injection	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po aspirin chew tab ngt hydromorphone hcl intraven	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po hydromorphone hcl intraven vancomycin in ivpb zolpidem tartrate oral hydrochlorothiazide oral
CU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan levofloxacin furosemide device pneumococcal im albuterol sulfate inhl alteplase injection ipratropium - albuterol inhl	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po aspirin chew tab ngt hydromorphone hcl intraven pneumococcal im vancomycin in ivpb albuterol sulfate inhl	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po hydromorphone hcl intraven vancomycin in ivpb zolpidem tartrate oral hydrochlorothiazide oral hydromorphone hcl intraven
ICU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan levofloxacin furosemide device pneumococcal im albuterol sulfate inhl alteplase injection ipratropium - albuterol inhl aspirin chew tab ngt	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po aspirin chew tab ngt hydromorphone hcl intraven pneumococcal im vancomycin in ivpb albuterol sulfate inhl ipratropium - albuterol inhl	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po hydromorphone hcl intraven vancomycin in ivpb zolpidem tartrate oral hydrochlorothiazide oral hydromorphone hcl intraven aspirin chew tab ngt
ICU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan levofloxacin furosemide device pneumococcal im albuterol sulfate inhl alteplase injection ipratropium - albuterol inhl aspirin chew tab ngt hydrochlorothiazide oral	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po aspirin chew tab ngt hydromorphone hcl intraven pneumococcal im vancomycin in ivpb albuterol sulfate inhl ipratropium - albuterol inhl hydrochlorothiazide oral	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po hydromorphone hcl intraven vancomycin in ivpb zolpidem tartrate oral hydrochlorothiazide oral hydromorphone hcl intraven aspirin chew tab ngt metronidazole po
ICU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan levofloxacin furosemide device pneumococcal im albuterol sulfate inhl alteplase injection ipratropium - albuterol inhl aspirin chew tab ngt hydrochlorothiazide oral vancomycin in ivpb	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po aspirin chew tab ngt hydromorphone hcl intraven pneumococcal im vancomycin in ivpb albuterol sulfate inhl ipratropium - albuterol inhl hydrochlorothiazide oral restoril oral	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po hydromorphone hcl intraven vancomycin in ivpb zolpidem tartrate oral hydrochlorothiazide oral hydromorphone hcl intraven aspirin chew tab ngt metronidazole po cefepime hcl intravenous
ICU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan levofloxacin furosemide device pneumococcal im albuterol sulfate inhl alteplase injection ipratropium - albuterol inhl aspirin chew tab ngt hydrochlorothiazide oral vancomycin in ivpb metronidazole po	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po aspirin chew tab ngt hydromorphone hcl intraven pneumococcal im vancomycin in ivpb albuterol sulfate inhl ipratropium - albuterol inhl hydrochlorothiazide oral restoril oral lipitor po	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po hydromorphone hcl intraven vancomycin in ivpb zolpidem tartrate oral hydromorphone hcl intraven aspirin chew tab ngt metronidazole po cefepime hcl intravenous alteplase injection
ICU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan levofloxacin furosemide device pneumococcal im albuterol sulfate inhl alteplase injection ipratropium - albuterol inhl aspirin chew tab ngt hydrochlorothiazide oral vancomycin in ivpb metronidazole po lactulose oral	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po aspirin chew tab ngt hydromorphone hcl intraven pneumococcal im vancomycin in ivpb albuterol sulfate inhl ipratropium - albuterol inhl hydrochlorothiazide oral restoril oral lipitor po metronidazole po	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po hydromorphone hcl intraven vancomycin in ivpb zolpidem tartrate oral hydromorphone hcl intraven aspirin chew tab ngt metronidazole po cefepime hcl intravenous alteplase injection bumetanide
ICU	cefepime hcl intravenous metronidazole po levofloxacin po hydromorphone hcl intraven lovenox subcutan levofloxacin furosemide device pneumococcal im albuterol sulfate inhl alteplase injection ipratropium - albuterol inhl aspirin chew tab ngt hydrochlorothiazide oral vancomycin in ivpb metronidazole po	furosemide device levofloxacin po alteplase iv lovenox subcutan hydrochlorothiazide oral metronidazole po aspirin chew tab ngt hydromorphone hcl intraven pneumococcal im vancomycin in ivpb albuterol sulfate inhl ipratropium - albuterol inhl hydrochlorothiazide oral restoril oral lipitor po	cefepime hcl intravenous pneumococcal im ipratropium - albuterol inhl lovenox subcutan levofloxacin levofloxacin po hydromorphone hcl intraven vancomycin in ivpb zolpidem tartrate oral hydromorphone hcl intraven aspirin chew tab ngt metronidazole po cefepime hcl intravenous alteplase injection

Table 12: Top features for "Disease of the digestive system" prediction models with DescEmb and CodeEmb

MIMIC-III	$\mathrm{DescEmb}$		CodeEmb
	RNN-Scr	Bert-FT	RD
	omeprazole prilosec	omeprazole prilosec	promethazine hcl po
	ranitidine prophylaxis	ranitidine prophylaxis	misoprostol po
	triamcinolone acetonide 0. 1 % cream tp	carafate sucralfate	omeprazole prilosec
	carafate sucralfate	protonix mg / hr	carafate sucralfate
	promethazine hcl po	promethazine hcl po	lansoprazole prevacid
	dialysate in	criticare hn	protonix mg / hr
	bismuth subsalicylate po	bismuth subsalicylate po	ranitidine prophylaxis
	isosource 1. 5 full	deliver 2. 0	pd fluid in
	beneprotein	probalance full	prazosin po
	nutren pulmonary full	nutren pulmonary	isosource 1. 5 full
	criticare hn	beneprotein	nutren 2. 0 full
	deliver 2. 0	misoprostol po	gray top hold plasma
	lupus anticoagulant	prazosin po	probalance full
	lansoprazole prevacid	ranitidine prophylaxis	fibersource hn full
	probalance full	pd fluid in	nutren pulmonary
	peptamen 1. 5 full	nutren 2. 0 full	peptamen 1. 5 full
	misoprostol po	isosource 1. 5 full	wright giemsa
	protonix mg / hr	dialysate in	pyrimethamine desensitization po
	phenytoin free	triamcinolone acetonide 0. 1 % cream tp	criticare hn
	wright giemsa	peptamen 1. 5 full	lidocaine 5% ointment tp
eICU			
	famotidine per g tube	famotidine per g tube	colace po
	docusate sodium per ng tube	famotidine iv	levofloxacin po
	colace po	docusate sodium per ng tube	famotidine per g tube
	docusate sodium colace capsule po	colace po	famotidine iv
	famotidine iv	docusate sodium colace capsule po	docusate sodium colace capsule po
	levofloxacin po	prolactin	docusate sodium per ng tube
	hydromorphone hcl intraven	levofloxacin po	chlorhexidine gluconate mouth rins
	thiamine po	lactulose oral	metronidazole ivpb
	prolactin	hydromorphone hcl intraven	prolactin
	chlorhexidine gluconate mouth rinse	chlorhexidine gluconate mouth rinse	albumin human iv
	lactulose oral	albumin human iv	hydromorphone hcl intraven
	cryoprecipitate	thiamine po	$d5~0.45\%~\mathrm{ns}$
	albumin human iv	metronidazole ivpb	thiamine po
	metronidazole ivpb	lactulose oral	vancomycin hcl in dextrose iv

d
5. 45
ns 40
kcl

pantoprazole iv

flagyl iv

lanoxin oral

 ${\bf cryoprecipitate}$

sterile water w / 3 amps bicarb

lactulose oral

octreotide

bumetanide

cryoprecipitate potassium chloride device

potassium phosphate dibasic iv

vancomycin hcl in dextrose iv

potassium chloride device

sterile water w / 3 amps bicarb

potassium phosphate dibasic iv zolpidem tartrate oral

tirofiban